HC Wainwright Brokers Lower Earnings Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – HC Wainwright decreased their Q3 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.47 per share for the quarter, down from their previous forecast of $0.51. HC Wainwright currently has a “Buy” rating and a $190.00 target price on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at $1.33 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.21) by $0.48. The company had revenue of $71.53 million for the quarter, compared to analysts’ expectations of $70.38 million. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%.

Several other equities analysts also recently weighed in on AXSM. UBS Group assumed coverage on Axsome Therapeutics in a research note on Tuesday, February 6th. They issued a “buy” rating and a $111.00 price objective for the company. Citigroup cut their price objective on Axsome Therapeutics from $127.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday. Morgan Stanley upgraded Axsome Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $90.00 to $115.00 in a report on Monday, April 29th. Guggenheim raised their price target on Axsome Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Finally, Piper Sandler upped their price objective on Axsome Therapeutics from $90.00 to $113.00 and gave the company an “overweight” rating in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $121.92.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $73.68 on Thursday. The firm’s fifty day simple moving average is $73.84 and its 200-day simple moving average is $75.72. Axsome Therapeutics has a fifty-two week low of $55.02 and a fifty-two week high of $98.40. The company has a quick ratio of 3.52, a current ratio of 3.63 and a debt-to-equity ratio of 0.93. The stock has a market cap of $3.50 billion, a PE ratio of -11.55 and a beta of 1.13.

Insiders Place Their Bets

In other news, COO Mark L. Jacobson sold 24,662 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Roger Jeffs sold 29,976 shares of Axsome Therapeutics stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $69.70, for a total value of $2,089,327.20. Following the transaction, the director now owns 120,756 shares in the company, valued at $8,416,693.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The disclosure for this sale can be found here. 24.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Axsome Therapeutics

A number of large investors have recently modified their holdings of AXSM. Blair William & Co. IL grew its holdings in shares of Axsome Therapeutics by 645.9% during the 1st quarter. Blair William & Co. IL now owns 63,547 shares of the company’s stock worth $5,071,000 after purchasing an additional 55,027 shares during the period. ProShare Advisors LLC lifted its position in Axsome Therapeutics by 9.0% during the first quarter. ProShare Advisors LLC now owns 9,724 shares of the company’s stock valued at $776,000 after buying an additional 800 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Axsome Therapeutics by 5,550.0% during the first quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock worth $63,000 after buying an additional 777 shares during the period. Sei Investments Co. increased its position in shares of Axsome Therapeutics by 8.2% in the first quarter. Sei Investments Co. now owns 35,654 shares of the company’s stock worth $2,845,000 after acquiring an additional 2,697 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Axsome Therapeutics by 605.5% in the first quarter. SG Americas Securities LLC now owns 15,104 shares of the company’s stock worth $1,205,000 after acquiring an additional 12,963 shares in the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.